NEWS
News
News
A novel agent, para-toluenesulfonamide, for the management of malignant pleural effusions.
Gongwin Biopharm at APCB 2025 Taipei
Academic Activities
Gongwin Biopharm at APCB 2025 Taipei
Academic Activities
ASCO-A novel agent, para-toluenesulfonamide, for the management of malignant pleural effusions.
About

A company focused on new drug development for solid tumors.
An innovative therapeutic approach - MITTA (Minimally Invasive Targeted Tumor Ablation)

We are a human- and pet-focused drug discovery and development company with in-house R&D and manufacturing, pioneering new paths in cancer drug development and continuing to focus on "PTS (Para Toluenesulfonamide)" cancer drug development, as well as new drugs for various luminal tissue tumor therapies and other new drugs not yet marketed in the marketplace, with the goal of providing physicians and patients with effective, high-quality, and innovative medicines.

READ MORE

Cooperative institutes

121

facilities

Indications

22

types

R&D experience

24

years

Arrival countries

15+

 

Product
Cooperative institutes
Dr. Teng Small Animal Clinic
Tongji University Affiliated Shanghai Pulmonary Hospital
Shanghai General Hospital
TZUOO-ANN Animal Hospital
West China Hospital of Sichuan University
Dr. Teng Small Animal Clinic
Tongji University Affiliated Shanghai Pulmonary Hospital
Shanghai General Hospital
TZUOO-ANN Animal Hospital
West China Hospital of Sichuan University
Dr. Teng Small Animal Clinic
Tongji University Affiliated Shanghai Pulmonary Hospital
Shanghai General Hospital
TZUOO-ANN Animal Hospital
West China Hospital of Sichuan University